FDA Approves Pafolacianine for the Detection of Ovarian Cancer Lesions

On November 29, 2021, the U.S. Food and Drug Administration (FDA) approved pafolacianine, an imaging drug intended to assist surgeons in identifying ovarian cancer lesions. The drug is designed to improve the ability to locate additional ovarian cancerous tissue that is normally difficult to detect during surgery.

Read the FDA announcement.

Read On Target Laboratories, Inc.'s announcement.

Posted 11/20/2021